Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Other Non Operating Income: 2019-2025

Historic Other Non Operating Income for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $10.4 million.

  • Kymera Therapeutics' Other Non Operating Income rose 7.70% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.5 million, marking a year-over-year increase of 13.70%. This contributed to the annual value of $38.0 million for FY2024, which is 102.65% up from last year.
  • Kymera Therapeutics' Other Non Operating Income amounted to $10.4 million in Q3 2025, which was up 29.72% from $8.1 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Other Non Operating Income peaked at $10.4 million during Q3 2025, and registered a low of $98,000 during Q2 2021.
  • Moreover, its 3-year median value for Other Non Operating Income was $8.9 million (2025), whereas its average is $7.7 million.
  • In the last 5 years, Kymera Therapeutics' Other Non Operating Income slumped by 66.19% in 2021 and then spiked by 2,537.24% in 2022.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Other Non Operating Income stood at $145,000 in 2021, then spiked by 2,537.24% to $3.8 million in 2022, then surged by 30.65% to $5.0 million in 2023, then soared by 101.40% to $10.1 million in 2024, then increased by 7.70% to $10.4 million in 2025.
  • Its last three reported values are $10.4 million in Q3 2025, $8.1 million for Q2 2025, and $8.9 million during Q1 2025.